Market Overview

UPDATE: Oppenheimer Initiates NPS Pharmaceuticals with Outperform on Leading Assets

Related NPSP
3 Niche ETFs Breaking Out
Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

In a report published Tuesday, Oppenheimer analyst Boris Peaker initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Outperform rating and $18.00 price target.

In the report, Peaker noted, “NPS is a biopharmaceutical company with two leading assets, Gattex and Natpara. Both drugs are first-in-class compounds, and as such, there are no direct competitors. Furthermore, we believe that both drugs offer significant benefit to patients, which in our view, will help commercial adoption. Although some investors may be concerned about owning a ‘launch name,' we believe that both Gattex and Natpara will generate substantial commercial traction given their therapeutic benefits, and as such, we see significant upside from current valuation.”

NPS Pharmaceuticals closed on Tuesday at $13.24.

Latest Ratings for NPSP

Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Initiation Analyst Ratings


Related Articles (NPSP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters